Clinical Studies2020-04-15T13:22:56-06:00

Clinical Studies

ProLung’s research team is continually expanding clinical evidence for the ProLung Test, bioconductance, and non-invasive lung cancer risk stratification through ongoing clinical studies and trials.

Completed Trials

PLW-216

This clinical validation study evaluated the safety and efficacy of the ProLung Test for risk stratification of patients with pulmonary lesions identified by CT that are suspicious for lung cancer. The ProLung Test’s performance from this clinical trial are the highest combined sensitivity and specificity values for a truly non-invasive solution that is pursuing FDA clearance for a lung cancer diagnostic that the Company is aware of. PLW-216 was conducted at the following research sites:

Fudan University
Jiaotong University
Tongji University
Nantong University
(led by Professor Chunxue, MD & PhD, FCCP, Bai at Fudan University)

PLW-216 RESULTS
PLW-216 AT ISRD & ATS JOINT-MEDICAL MEETING

PL-208

This study evaluated the safety and efficacy of the ProLung Test for risk stratification of patients with pulmonary lesions identified by CT that are suspicious for lung cancer. PL-208 was conducted at the following research sites:

Huntsman Cancer Institute
Henry Ford Hospital
University of California Los Angeles
Loyola University Health System
Greater Baltimore Medical Center
University of Minnesota Masonic Cancer Center
Medical University of South Carolina
Mayo Clinic

Stanford Health Care
MD Anderson Cancer Center
Intermountain Health Care
University of California San Diego
Providence Healthcare
Wake Forest Baptist Health
Beth Israel Deaconess Boston

PL-208 RESULTS
CLINICAL TRIALS

PL-209

The PL-209 repeatability study objectives include quantifying the effects of sex, body mass index (BMI), day-to-day subject variability of a single device when volume – average thoracic bioconductance was measured with the ProLung Test. The study enrolled sixty subjects.

PL-209 RESULTS

FML-204

The FML-204 study was a prospective study of 41 patients to evaluate the safety and efficacy of non-invasive, non-radiating bioconductance measurements in distinguishing between malignant and benign lung lesions. No adverse events reported.

FML-204 RESULTS

Transcutaneous Computed Bioconductance Measurement in Lung Cancer
Rex C. Yung, MD; Ming Ying Zeng, MD; Gregory J. Stoddard, MS; Michael Garff, BS; and Karleen Callahan, PhD.
J Thorac Oncol. Vol. 7, No. 4, April 2012

If you have been diagnosed with an indeterminate pulmonary nodule, you may be eligible to participate in a ProLung clinical trial.
Email us at ItsAboutTime@prolunginc.com and we will connect you to the nearest testing location.